EMEA-002924-PIP02-23 - paediatric investigation plan

etavopivat
PIPHuman

Key facts

Active Substance
etavopivat
Therapeutic area
Congenital, familial and genetic disorders
Decision number
P/0158/2024
PIP number
EMEA-002924-PIP02-23
Pharmaceutical form(s)
  • Tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of sickle cell disease
Route(s) of administration
Oral use
Contact for public enquiries

Novo Nordisk A/S

E-mail: paediatrics@novonordisk.com 
Tel.: +45 44448888

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page